Top

Published in:

01-03-2008 | Brief Report

An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins

Authors: Oliver P. Windram, Brandon Weber, Mohamed A. Jaffer, Edward P. Rybicki, Dionne N. Shepherd, Arvind Varsani

Published in: Archives of Virology | Issue 3/2008

Abstract

Development of vaccine strategies against human papillomavirus (HPV), which causes cervical cancer, is a priority. We investigated the use of virus-like particles (VLPs) of the most prevalent type, HPV-16, as carriers of foreign proteins. Green fluorescent protein (GFP) was fused to the N or C terminus of both L1 and L2, with L2 chimeras being co-expressed with native L1. Purified chimaeric VLPs were comparable in size (∼55 nm) to native HPV VLPs. Conformation-specific monoclonal antibodies (Mabs) bound to the VLPs, thereby indicating that they possibly retain their antigenicity. In addition, all of the VLPs encapsidated DNA in the range of 6–8 kb.

Available only for authorised users

Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin DD, Orth G, Schiller JT, Lowy DR (1995) Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69:3959–3963PubMed

Finnen RL, Erickson KD, Chen XS, Garcea RL (2003) Interactions between papillomavirus L1 and L2 capsid proteins. J Virol 77:4818–4826PubMedCrossRef

Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4:46–55PubMedCrossRef

Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT (1998) Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800–1805PubMedCrossRef

Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR (1995) Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13:1509–1514PubMedCrossRef

Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T (1998) In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol 72:10298–10300PubMed

Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH (2000) Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes (in process citation). Virology 273:374–382PubMedCrossRef

Liu XS, Liu WJ, Zhao KN, Liu YH, Leggatt G, Frazer IH (2002) Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol 80:21–29PubMedCrossRef

Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, Shi L (2006) Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 95:2195–2206PubMedCrossRef

10.

Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L (1997) Chimeric papillomavirus-like particles. Virology 234:93–111PubMedCrossRef

11.

Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Muller M, Kast WM (1999) Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 73:145–152PubMedCrossRef

12.

Peng S, Frazer IH, Fernando GJ, Zhou J (1998) Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240:147–157PubMedCrossRef

13.

Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT (1996) In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 70:5875–5883PubMed

14.

Rossi JL, Gissmann L, Jansen K, Muller M (2000) Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae. Hum Gene Ther 11:1165–1176PubMedCrossRef

15.

Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I (1999) Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 81:881–888PubMedCrossRef

16.

Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553–11557PubMedCrossRef

17.

Touze A, Coursaget P (1998) In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 26:1317–1323PubMedCrossRef

18.

Unckell F, Streeck RE, Sapp M (1997) Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 71:2934–2939PubMed

19.

Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP (2003) Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 77:8386–8393PubMedCrossRef

20.

Varsani A, Williamson AL, Jaffer MA, Rybicki EP (2006) A deletion and point mutation study of the human papillomavirus type 16 major capsid gene. Virus Res 122:154–163PubMedCrossRef

21.

Zhao KN, Sun XY, Frazer IH, Zhou J (1998) DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243:482–491PubMedCrossRef

Title: An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins
Authors: Oliver P. Windram
Brandon Weber
Mohamed A. Jaffer
Edward P. Rybicki
Dionne N. Shepherd
Arvind Varsani
Publication date: 01-03-2008
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 3/2008
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-007-0025-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Complete nucleotide sequences and genome characterization of a novel double-stranded RNA virus infecting Rosa multiflora

Panicum streak virus diversity is similar to that observed for maize streak virus

Biological and molecular characterization of tospoviruses in Thailand

Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine

Identical rearrangement of NSP3 genes found in three independently isolated virus clones derived from mixed infection and multiple passages of Rotaviruses

Cellular binding partners of the human papillomavirus E6 protein

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials